HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.3250
+0.0100 (+3.17%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.3150
Open0.0000
Bid0.320 x 0
Ask0.325 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume12,040,480
Market Cap446.423M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.002
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 days ago

    FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

    SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.

  • Newsfile6 days ago

    FSD Pharma, Plans for Becoming the Largest Producer in the World, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - January 15, 2019) - Rupert Haynes, CEO of FSD Pharma speaks about pivoting from medical marijuana to a pharmaceutical company.If you cannot view the video above, please visit:https://www.b-tv.com/fsd-pharma-ceo-clips-90sec/FSD Pharma is being featured on BNN Bloomberg on Jan. 19 - Jan. 20, 2019, throughout the day and evenings.FSD Pharma (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. ...

  • Business Wire7 days ago

    FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

    FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Anthony Durkacz, Co-Chairman of the Board and Co-Founder of FSD, said, "I want to congratulate Zohar Krivorot and his team at Cannara for achieving this significant milestone and for their ongoing efforts to build out the largest indoor cannabis grow facility in Quebec.

  • FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE
    CNW Group7 days ago

    FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

    TORONTO , Jan. 14, 2019 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate Cannara Biotech Inc. ("Cannara") for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Anthony Durkacz , Co-Chairman of the Board and Co-Founder of FSD, said, "I want to congratulate Zohar Krivorot and his team at Cannara for achieving this significant milestone and for their ongoing efforts to build out the largest indoor cannabis grow facility in Quebec .

  • CNW Group9 days ago

    FSD Pharma Announces Holdings in Cannara Biotech Inc.

    TORONTO , Jan. 11, 2019 /CNW/ - FSD Pharma ("FSD") announced today that, in connection with the business combination (the "Business Combination") completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the "Issuer"), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.

  • Business Wire13 days ago

    FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations.

  • FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot
    CNW Group13 days ago

    FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

    TORONTO , Jan. 8, 2019 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations.

  • Newsfile28 days ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's Investment in Cannabis Retailer, Huge Shops, Gaining Strategic Access to Chairman's Brands' Coffee Time Retail Network - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - December 24, 2018) -  FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a licensed cannabis producer, has invested $1.3 million to acquire approximately 9.9% of Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with privately held Chairman's Brands, based in Toronto, and one of the largest and fastest growing franchising companies in Canada, with a global presence in Europe and the Middle East.InvestmentPitch.com has ...

  • Business Wirelast month

    FSD Pharma Responds to Therapix Termination of Binding LOI

    On October 22, FSD Pharma announced the signing of the binding LOI to acquire Therapix Biosciences as part of the company’s strategic objective to develop pharmaceutical assets in the cannabinoid research space.

  • GlobeNewswirelast month

    Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media

    SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.

  • Business Wirelast month

    FSD Pharma Announces Strategic Investment in Huge Shops

    FSD Pharma Inc. (“FSD Pharma” or “FSD”) (HUGE.CN) (FSDDF) (0K9.F) has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide.

  • FSD Pharma Announces Strategic Investment in Huge Shops
    CNW Grouplast month

    FSD Pharma Announces Strategic Investment in Huge Shops

    TORONTO , Dec. 20, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto -based cannabis retailer. Huge Shops has a strategic alliance with Chairman's Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide.

  • FSD Pharma Congratulates High Tide for Its Listing and Commencement of Trading on the CSE
    CNW Grouplast month

    FSD Pharma Congratulates High Tide for Its Listing and Commencement of Trading on the CSE

    TORONTO , Dec. 17, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate High Tide Inc. ("High Tide") for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "HITI".  FSD has been a founding shareholder of High Tide since participating in its non-brokered private placement that closed on May 2, 2018 , while adding to its position by participating in High Tide's offering of special warrants that closed on October 2, 2018 . Anthony Durkacz , Co-Chairman of the Board and Founder of FSD, said, "I am extremely proud of Raj Grover and his team at High Tide for achieving this incredible milestone.

  • Business Wirelast month

    FSD Pharma Congratulates High Tide for Its Listing and Commencement of Trading on the CSE

    FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate High Tide Inc. (“High Tide”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "HITI". FSD has been a founding shareholder of High Tide since participating in its non-brokered private placement that closed on May 2, 2018, while adding to its position by participating in High Tide’s offering of special warrants that closed on October 2, 2018. Anthony Durkacz, Co-Chairman of the Board and Founder of FSD, said, "I am extremely proud of Raj Grover and his team at High Tide for achieving this incredible milestone.

  • ACCESSWIRElast month

    FSD Pharma Featured in the Cannabis Investor Magazine

    ATLANTA, GA / ACCESSWIRE / December 12, 2018 / CannaInvestor Magazine announced today FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is the featured company in the CannaInvestor ...

  • FSD Pharma Featured in CannaInvestor Magazine December Issue
    CNW Grouplast month

    FSD Pharma Featured in CannaInvestor Magazine December Issue

    TORONTO , Dec. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (HUGE.CN) (FSDDF) (0K9.F) today announced that it is the featured company in the CannaInvestor Magazine December 2018 Issue. CannaInvestor Magazine is the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and the financial media. FSD Pharma's cover feature can be found by clicking on this link https://joom.ag/0j5a or visiting CannaInvestor Magazine's website www.cannainvestormag.ca.

  • Business Wire2 months ago

    FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the “RTO”), and submitted its initial listing application to the Canadian Securities Exchange (the “CSE”) late last week.

  • FSD Pharma Announces Collaboration and License Agreement with World Class Extractions
    CNW Group2 months ago

    FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

    TORONTO , Dec. 6, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (HUGE.CN) (FSDDF) (0K9.F), which, through its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the "Agreement") with World Class Extractions Inc. ("World Class"), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the "RTO"), and submitted its initial listing application to the Canadian Securities Exchange (the "CSE") late last week. Under the terms of the agreement and a related lease, FSD Pharma will provide World Class with space at its 620,000 square foot facility in Cobourg, Ontario (the "FSD Facility"), assist it in obtaining an extraction license from Health Canada, and provide World Class with the raw cannabis needed to produce cannabis extracts.

  • Business Wire2 months ago

    FSD Pharma Congratulates Partner Canntab on Launch of Research Partnership with Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D.

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) (CSE:PILL) (TBF1.F) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.

  • FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.
    CNW Group2 months ago

    FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

    FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

  • Business Wire2 months ago

    FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

    FSD Pharma Inc. (“FSD” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange (“CSE”). During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. The Company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in another record-breaking launch into the Canadian cannabis marketplace.

  • FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months
    CNW Group2 months ago

    FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

    TORONTO , Dec. 3, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange ("CSE"). During the period of May 29, 2018 to November 29, 2018 , the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. The Company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in another record-breaking launch into the Canadian cannabis marketplace.

  • FSD Pharma Reports Positive Q3 Results
    CNW Group2 months ago

    FSD Pharma Reports Positive Q3 Results

    TORONTO , Nov. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) today reported its financial and operational results for the third quarter of fiscal 2018, ended September 30, 2018 .

  • Business Wire2 months ago

    FSD Pharma Reports Positive Q3 Results

    FSD Pharma Inc. today reported its financial and operational results for the third quarter of fiscal 2018, ended September 30, 2018.

  • Newsfile2 months ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's New $105 Million Facility Valuation, Potentially $420 Million with Completion of 3 Million Sq Ft Expansion - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a licensed cannabis producer, announced that according to a new official Comprehensive Property Value Assessment, its Cobourg, Ontario land and facility now has a Fair Market Value of $105 million. The facilities, the former Kraft plant, sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to ...